EUCTR2006-003712-22-DE进行中（未招募）不适用
Pharmacokinetics of UDCA in serum and bile in patients with early stage PBC (stage I-III) and in healthy volunteers
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •All subjects:
- •Male or female, adult, body mass index in the range of 18-30 kg/m2, able to give fully informed written consent, clinically acceptable vital signs and ECG.
- •Positive anti-mitochondrial antibody testing, alkaline phosphatase or gamma-glutamyl-transpeptidase = 1.5 above normal at initial diagnosis, and within 5 years prior to inclusion histologically proven non-cirrhotic liver disease compatible with PBC stage I, II, II-III and no reliable signs of portal hypertension such as esophageal varices or ascites and/or pylephlebectasia > 15 mm.
- •Volunteers:
- •Non-smokers, routine laboratory parameters within their normal range or deviations from normal range not clinically relevant according to the investigator.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •All subjects:
- •Existing cardiac, hematological, renal, gastrointestinal (other than PBC) diseases and/or pathological findings which might interfere with the drugs' safety, tolerability, absorption, pharmacokinetics and/or endoscopy; other acute or chronic diseases which might affect absorption or metabolism of UDCA; alcohol abuse; positive anti-HIV-test or HBs-Ag-test or anti-HCV-test; intake of cholestyramine or H2-antagonists within the last 3 days prior to first administration of study drug and during the study; intake of antacids within 12 hours prior to first administration of study drug and during the study; repeated intake of drugs which might interfere with gastrointestinal absorption and motility within the last 3 days prior to first administration of study drug and during the study; known allergic reactions to the active ingredients used or to constituents of the pharmaceutical preparations; acute inflammation of the gallbladder or bile duct system; obstruction of the bile ducts; acute hepatitis; patients/volunteers suspected not be able to understand or follow instructions; patients/volunteers in financial difficulties; blood donation or other blood loss of more than 400 ml within the previous 2 months; women of child-bearing potential without two independent methods of contraception.
- •Any other hepatic disease of metabolic, viral and/or toxic origin, secondary biliary cirrhosis, other autoimmune hepatitis than PBC; clinically relevant pathological laboratory findings not related to hepatic disorder; histologically proven cirrhotic liver disease or total bilirubin > 3 mg/dl or reliable signs of portal hypertension; complete thrombosis of the portal vein; heavy smokers; pregnant/lactating women; intake of UDCA in the 6 weeks prior to Study Day 1; increases in at least two of the following five liver parameters by = 4 times the upper limit of normal after 4 weeks of UDCA wash-out: AST, ALT, ?-GT, total bilirubin, alkaline phosphatase.
- •Volunteers:
- •History or clinical evidence of any cardiac, cardio-vascular, hepatic, cholangiolar, renal, pulmonary, endocrine, neurologic, infectious, gastrointestinal, hematological, oncological, psychiatric disease or emotional problems or any other clinical relevant condition, physical finding, laboratory test abnormality which, in the opinion of the Investigator, would pose a significant risk to the volunteer, invalidate the giving of the informed consent or limit the ability of the volunteer to comply with study requirements or interfere otherwise with the conduct of the study, any medication within the last 14 days prior to or during the conduct of the study.
研究者
相似试验
尚未招募
不适用
Pharmacokinetics of UDCA in serum and bile in patients with early stage PBC (stage I-III) and in healthy volunteersearly stage primary biliary cirrhosis10019654PBCNL-OMON31024Dr. Falk Pharma GmbH10
已完成
1 期
Pharmacokinetic Investigation of UDCA in Bile and SerumHealthyNCT00529009Dr. Falk Pharma GmbH
已完成
不适用
The Effect of UrsodeoXyCholicacid (UDCA) and ezetimibe on total faecal steRol ExcreTion and plasma lipid lEvels1001980610013317Familial hypercholesterolemiaNL-OMON47926Academisch Medisch Centrum (AMC)20
招募中
不适用
The Pharmacokinetics of an oral uracil dose in patients with colorectal carcinoma.DPD deficiencyPharmacokineticscolorectalDPD deficiëntiekinetiekuracilcolorectaalNL-OMON28016eveste Scheper ziekenhuisLeids Universitair medische CentumLeveste Scheper ZiekenhuisBoermarkeweg 607824 AA EmmenPostadresPostbus 30.0027800 RA Emmen24
已完成
不适用
Studie naar het effect van ursodeoxycholzuur (ursochol) en ezetimibe op de uitscheiding van vetten in de ontlasting en op de concentratie van vetten in het bloedNL-OMON19907Academisch Medisch Centrum (AMC), Amsterdam20